The standard of NAD measuring
Investors 1
Funding Rounds 2
| Date | Series | Amount | Investors |
| 02.12.2025 | - | $30K | - |
| 22.08.2024 | Series A | $3.89M | - |
Mentions in press and media 6
| Date | Title | Description |
| 02.12.2025 | Biotech scaleup NADMED launches $30K global award to advance innovation in cellular health | As scientists seek to understand the molecular basis of energy production, ageing, and disease, one area remains especially elusive: cellular redox metabolites.
Finnish biotech company NADMED is launching the NADMED Award 2026, a global cal... |
| 22.08.2024 | NADMED raises €3.5M to bring NAD tests to international markets, advancing personalized treatment options | NADMED raises €3.5M to bring NAD tests to international markets, advancing personalized treatment options
Thu, Aug 22, 2024 10:30 CET Report this content
Finnish biotech company NADMED has developed the first test to measure all four bodily... |
| 22.08.2024 | Biotech NADMED raises €3.5M series A for 'NAD' vitals testing | Finnish biotech company NADMED has raised €3.5M for its blood testing technology. The round was led by Finnish science-based startup investor Nordic Science Investments (NSI). Additional funding was secured from previous investors Voima Ven... |
| 22.08.2024 | Finnish biotech NADMED raises €3.5 million Series A for vitamin B3 deficiencies testing | Helnsinki-based NADMED has closed a €3.5 million series A round to fund its entry to the U.S. and other international markets with its proprietary nicotinamide adenine dinucleotide (NAD) measurement technology that may help clinicians estab... |
| 22.08.2024 | Nadmed Raises €3.5M in Series A Funding | Nadmed, a Helsinki, Finland-based biotech company developing a testing method to measure all four NADs*, raised €3.5M in Series A funding.
The round was led by Nordic Science Investments (NSI) with participation from previous investors Voim... |
| - | NADMED | “The standard of NAD measuring” |
Reviews 0
